Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Rowan Paul: MSCs Show Strongest Pain Reduction in Regenerative Medicine Approaches
Rowan Paul/LinkedIn
Feb 7, 2026, 15:29

Rowan Paul: MSCs Show Strongest Pain Reduction in Regenerative Medicine Approaches

Rowan Paul, Sports Medicine and Interventional Regenerative Orthobiologics Physician at RegenCore, shared on LinkedIn:

”My key takeaway is that MSCs showed the strongest pain reduction. Nice to see this born out in the peer reviewed literature. Happy to be doing Prospective Clinical Trial research.

PRP

Efficacy:

  • Best for acute injuries and tendon repair-patellar tendinopathy, knee OA, lateral epicondylitis
  • Superior to corticosteroids and HA
  • Limited success in chronic conditions:

Limitations

  • Hard to generalize across all indications. be precise in formulation of your PRP depending on structure, patient, and goals
  • Inconsistent preparation methods
  • Optimal: LP- PRP, weekly × 3 weeks
  • Requires 10-12 billion cumulative over course:

Mechanism

  •  VEGF, PDGF, TGF-β release stimulates angiogenesis and matrix synthesis[1]

Mesenchymal Stem Cells (MSCs)

Efficacy:

  • Highest pain reduction among all modalities
  • Cartilage regeneration in early OA
  • Sustained improvements at 12-24 months

Mechanism

  •  Immunomodulation, reduced inflammation, M2 macrophage polarization

Major Barriers:

  • High costs and ethical concerns
  •  Experimental
  • Symptomatic relief insufficient to justify costs on a system level

Peptide-Based Therapies

  •  Moderate improvements; promising for infection control and wound healing
  •  Limited evidence (10 studies)
  •  Needs optimization of dosing, delivery, safety

Biomimetic Materials

  •  Scaffolds, Autologous Protein Solutions, PRF.
  • Lowest efficacy in meta-analysis[1]

Clinical Practice Insights

Standardization Challenges:

  •  Variable methods and heterogeneous formulations= inconsistent results
  •  Insufficient reporting limits evidence synthesis
  •  This is a particular interest of mine and we need more research

Evidence Characterization:

  • ‘Symptom-modifying’ vs ‘structure-modifying’—improve pain/function but limited true regeneration
  •  Short/mid-term results noticeable; long-term stability undetermined
  • Need long-term follow-up to see structural changes

Precision Medicine Need:

  •  Must identify potency markers to match treatments to tissues/pathologies
  • Improved mechanistic understanding enables precision approaches

Market Landscape

  •  51.5% of publications focus on PRP, 30.8% bone marrow, 15.2% adipose-derived cells. We need more MSC research as well as scaffolding research and this takes investment and funding.”

Title: Advancements in Regenerative Therapies for Orthopedics: A Comprehensive Review of Platelet-Rich Plasma, Mesenchymal Stem Cells, Peptide Therapies, and Biomimetic Applications

Authors: Andrew J Goulian, Brielle Goldstein, Maarouf A Saad

Read the Full Article on National Library of Medicine.

Rowan Paul: MSCs Show Strongest Pain Reduction in Regenerative Medicine Approaches

Stay updated on all scientific advances with Hemostasis Today.

 

Andrew J Goulian Brielle Goldstein Health Hematology Hemostasis Hemostasis News Hemostasis Today Maarouf A Saad . Medicine Rowan Paul thrombosis
NewsFeed